Microbion
Bozeman, US · Delaware corporation · 1 known investors
Microbion develops therapeutics targeting biofilm-associated infections, with a lead candidate (Pravibismane) in clinical development for diabetic foot ulcer, orthopedic implant, and respiratory infections. The company operates in the biotech industry.
Founders & leadership
KL
Karim LaljiExecutive
FK
Frank KerinsExecutive
BB
Brett BakerFounder, President & Chief Innovation Officer
Board
RM
Rodger MayBoard director
JC
Jared CarneyBoard director
SS
Steven SchellongBoard director
JL
Julia LevyBoard director
JH
Jason HarmonBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$43.1M disclosed across 3 rounds · 2014–2021
▶$11.9MraisedJul 2021 · 18 investors · PharmaceuticalsRule 506(b)
▶$11.9MraisedJul 2021 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brett BakerExecutive Officer, Director
- Robert GillamDirector
- Jarret ShaDirector
- Jason HarmonDirector
- Karim LaljiDirector
- Kaley WilsonDirector
- Offering amount
- $13.4M
- Amount sold
- $11.9M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25.4MraisedJan 2017 · 11 investors · BiotechnologyRule 506(b)
▶$25.4MraisedJan 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karim LaljiDirector
- Jason HarmonDirector
- Zafrira AvnurDirector
- Roger KuypersDirector
- Brett BakerExecutive Officer, Director
- Offering amount
- $51.3M
- Amount sold
- $25.4M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.9MraisedJan 2016 · 33 investors · BiotechnologyRule 506(b)
▶$5.9MraisedJan 2016 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rodger MayDirector
- Jared CarneyDirector
- Steven SchellongDirector
- Karim LaljiExecutive Officer, Director
- Julia LevyDirector
- Jason HarmonDirector
- Brett BakerExecutive Officer, Director
- Frank KerinsExecutive Officer
- Offering amount
- $8.5M
- Amount sold
- $5.9M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Vividion Therapeutics15 shared keywordsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
bio10 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Companies competing with Microbion for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Microbion do?
- Microbion develops therapeutics targeting biofilm-associated infections, with a lead candidate (Pravibismane) in clinical development for diabetic foot ulcer, orthopedic implant, and respiratory infections. The company operates in the biotech industry.
- Who are Microbion's investors?
- Microbion's investors include Quark Venture Inc..
- How much funding has Microbion raised?
- Microbion has disclosed $43.1M raised across 3 rounds.
- Where is Microbion headquartered?
- Microbion is headquartered in Bozeman, US.